JP2012508164A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508164A5
JP2012508164A5 JP2011533633A JP2011533633A JP2012508164A5 JP 2012508164 A5 JP2012508164 A5 JP 2012508164A5 JP 2011533633 A JP2011533633 A JP 2011533633A JP 2011533633 A JP2011533633 A JP 2011533633A JP 2012508164 A5 JP2012508164 A5 JP 2012508164A5
Authority
JP
Japan
Prior art keywords
antibody construct
single chain
acute lymphoblastic
bispecific single
cd19xcd3 bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011533633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508164A (ja
JP5647132B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/007970 external-priority patent/WO2010052014A1/en
Publication of JP2012508164A publication Critical patent/JP2012508164A/ja
Publication of JP2012508164A5 publication Critical patent/JP2012508164A5/ja
Application granted granted Critical
Publication of JP5647132B2 publication Critical patent/JP5647132B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011533633A 2008-11-07 2009-11-06 急性リンパ芽球性白血病の治療 Active JP5647132B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US61/112,323 2008-11-07
US18329109P 2009-06-02 2009-06-02
US61/183,291 2009-06-02
PCT/EP2009/007970 WO2010052014A1 (en) 2008-11-07 2009-11-06 Treatment of acute lymphoblastic leukemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014226022A Division JP5955921B2 (ja) 2008-11-07 2014-11-06 急性リンパ芽球性白血病の治療

Publications (3)

Publication Number Publication Date
JP2012508164A JP2012508164A (ja) 2012-04-05
JP2012508164A5 true JP2012508164A5 (https=) 2013-03-21
JP5647132B2 JP5647132B2 (ja) 2014-12-24

Family

ID=41692882

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011533633A Active JP5647132B2 (ja) 2008-11-07 2009-11-06 急性リンパ芽球性白血病の治療
JP2014226022A Active JP5955921B2 (ja) 2008-11-07 2014-11-06 急性リンパ芽球性白血病の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014226022A Active JP5955921B2 (ja) 2008-11-07 2014-11-06 急性リンパ芽球性白血病の治療

Country Status (26)

Country Link
US (3) US20130323247A1 (https=)
EP (2) EP2982696B1 (https=)
JP (2) JP5647132B2 (https=)
KR (1) KR101695327B1 (https=)
CN (2) CN107184977A (https=)
AU (4) AU2009313040B2 (https=)
BR (1) BRPI0921482B1 (https=)
CA (1) CA2742249C (https=)
CY (2) CY1117033T1 (https=)
DK (2) DK2342227T3 (https=)
ES (2) ES2727585T3 (https=)
HR (2) HRP20151168T1 (https=)
HU (2) HUE043326T2 (https=)
IL (1) IL212652A (https=)
LT (1) LT2982696T (https=)
ME (2) ME02363B (https=)
MX (1) MX2011002927A (https=)
NZ (1) NZ591311A (https=)
PL (2) PL2982696T3 (https=)
PT (2) PT2342227E (https=)
RS (2) RS54456B1 (https=)
RU (1) RU2536940C2 (https=)
SI (2) SI2982696T1 (https=)
SM (2) SMT201900278T1 (https=)
WO (1) WO2010052014A1 (https=)
ZA (1) ZA201103255B (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1976886T3 (en) * 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
PT2342227E (pt) * 2008-11-07 2015-11-13 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda
CN107227335A (zh) 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案
NZ609201A (en) * 2010-10-27 2015-01-30 Amgen Res Munich Gmbh Means and methods for treating dlbcl
CN103533943B (zh) * 2010-11-10 2018-02-13 安进研发（慕尼黑）股份有限公司 由cd3特异性结合结构域导致的不良作用的预防
KR102345943B1 (ko) * 2011-04-28 2021-12-31 암젠 리서치 (뮌헨) 게엠베하 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
DK3105252T3 (da) * 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
ES2715679T3 (es) 2014-05-30 2019-06-05 Amgen Res Munich Gmbh Estratificación del riesgo de pacientes con leucemia linfoblástica aguda de precursores B
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
WO2016109549A1 (en) 2014-12-30 2016-07-07 University Of Utah Research Foundation Hdac1,2 inhibitors and methods of using the same
AU2016222830B2 (en) 2015-02-24 2021-02-25 Bioatla Llc Conditionally active biological proteins
CN107995913B (zh) * 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
RS66511B1 (sr) 2015-05-20 2025-03-31 Amgen Res Munich Gmbh Deplecija b ćelija kao dijagnostički marker
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN105154440B (zh) * 2015-08-14 2016-11-30 深圳市瀚海基因生物科技有限公司 一种基于高通量测序构建白血病微小残留病灶tcr文库的多重pcr引物和方法
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
RU2651776C2 (ru) * 2015-12-01 2018-04-23 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") Биспецифические антитела против cd3*cd19
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
KR20250111232A (ko) * 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) * 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
WO2020160310A1 (en) * 2019-01-30 2020-08-06 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific t-cell engagers targeting cancer antigens and methods of use in cancer theraputics
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
MX2021014644A (es) * 2019-06-13 2022-04-06 Amgen Inc Control de perfusion basado en biomasa automatizado en la fabricacion de productos biologicos.
WO2021183861A1 (en) 2020-03-12 2021-09-16 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4214233A1 (en) 2020-09-16 2023-07-26 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250282864A1 (en) 2021-10-15 2025-09-11 Amgen Research (Munich) Gmbh Subcutaneous administration of cd19-binding t cell engagers
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
BG65066B1 (bg) * 1998-04-21 2007-01-31 Micromet Gessellschaft Fur Biomedicinische Forschung Mbh CD19 x CD3 СПЕЦИФИЧНИ ПОЛИПЕПТИДИ И ТЯХНОТО ИЗПОЛЗВАНЕ
CZ302070B6 (cs) * 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
DE602004030811D1 (de) * 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
DK1976886T3 (en) * 2005-12-16 2015-03-02 Amgen Res Munich Gmbh Means and methods for the treatment of tumor diseases
CN101331151A (zh) * 2005-12-16 2008-12-24 麦克罗梅特股份公司 治疗肿瘤性疾病的方式和方法
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
PT2342227E (pt) * 2008-11-07 2015-11-13 Amgen Res Munich Gmbh Tratamento da leucemia linfoblástica aguda
CN102282129A (zh) * 2009-01-19 2011-12-14 雅培制药有限公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
CN102282128B (zh) * 2009-01-19 2015-06-17 Abbvie公司 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂
MX2011012632A (es) * 2009-05-27 2012-03-06 Abbott Lab Inhibidores de actividad de cinasa tipo pirimidina.
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
CN107227335A (zh) * 2009-10-27 2017-10-03 安进研发（慕尼黑）股份有限公司 用于施用CD19xCD3双特异性抗体的给药方案

Similar Documents

Publication Publication Date Title
JP2012508164A5 (https=)
JP2012508163A5 (https=)
HRP20151168T1 (hr) Lijeäśenje akutne limfoblastiäśne leukemije
Vebr et al. A narrative review of cytokine networks: pathophysiological and therapeutic implications for inflammatory bowel disease pathogenesis
HRP20191715T1 (hr) Liječenje dječje akutne limfoblastične leukemije sa bispecifičnim protutijelima protiv cd3xcd19
Jin et al. TL1A/TNFSF15 directly induces proinflammatory cytokines, including TNFα, from CD3+ CD161+ T cells to exacerbate gut inflammation
JP6367836B2 (ja) Ｔ制御性細胞の増殖または枯渇方法
Crane et al. CXCR4 receptor expression on human retinal pigment epithelial cells from the blood-retina barrier leads to chemokine secretion and migration in response to stromal cell-derived factor 1α
Peligero-Cruz et al. IL18 signaling promotes homing of mature Tregs into the thymus
US20200352999A1 (en) Use and production of engineered immune cells to disrupt nfat-ap1 pathway transcription factors
CN111593022B (zh) vMIP-Ⅱ诱导CD8+ T细胞去磷酸化为Tcm及其在药物中的应用
Ma et al. Ebi3 promotes T-and B-cell division and differentiation via STAT3
Kondo et al. Mouse gingival single-cell transcriptomic atlas identified a novel fibroblast subpopulation activated to guide oral barrier immunity in periodontitis
Liu et al. Prostaglandin I2-IP signalling regulates human Th17 and Treg cell differentiation
O’Neil et al. The role of tissue resident memory CD4 T cells in herpes simplex viral and HIV infection
Palmer et al. IFNγ-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment
WO2021216738A2 (en) Compositions and methods of generating an immune response
Koutsoumparis et al. Erythropoietin (rhEPOa) promotes endothelial transdifferentiation of stem cells of the apical papilla (SCAP)
JP2024167242A (ja) 誘導された制御性Ｔ（ｉＴＲＥＧ）細胞を使用したＡＬＳ治療
Van Belle et al. Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model
WO2022217373A1 (zh) 一种降低人免疫缺陷病毒感染的病毒设定点及重建细胞免疫的因子和药物应用
US20220305488A1 (en) Dynamic Profiling of Antitumor Activity of CAR T Cells Using Micropatterned tumor Array Devices
Sundaram et al. Measles virus nucleocapsid protein modulates the Signal Regulatory Protein-β1 (SIRPβ1) to enhance osteoclast differentiation in Paget's disease of bone
Choi The role of innate lymphoid cells in the heart and cardiac inflammation
US20260083778A1 (en) Generation of cd4 t cells